dc.creator | Sampson, James F. | |
dc.creator | Hasegawa, Eiichi | |
dc.creator | Mulki, Lama | |
dc.creator | Suryawanshi, Amol | |
dc.creator | Jiang, Shuhong | |
dc.creator | Chen, Wei Sheng | |
dc.creator | Rabinovich, Gabriel Adrian | |
dc.creator | Connor, Kip M. | |
dc.creator | Panjwani, Noorjahan | |
dc.date.accessioned | 2016-11-23T17:29:44Z | |
dc.date.accessioned | 2018-11-06T14:43:14Z | |
dc.date.available | 2016-11-23T17:29:44Z | |
dc.date.available | 2018-11-06T14:43:14Z | |
dc.date.created | 2016-11-23T17:29:44Z | |
dc.date.issued | 2015-06-30 | |
dc.identifier | Sampson, James F.; Hasegawa, Eiichi ; Mulki, Lama ; Suryawanshi, Amol ; Jiang, Shuhong; et al.; Galectin 8 ameliorates murine autoimmune ocular pathology and promotes a regulatory T cell response; Public Library Of Science; Plos One; 10; 6; 30-6-2015; 1-17; e130772 | |
dc.identifier | 1932-6203 | |
dc.identifier | http://hdl.handle.net/11336/8299 | |
dc.identifier | 1932-6203 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1889436 | |
dc.description.abstract | Galectins have emerged as potent immunoregulatory agents that control chronic inflammation through distinct mechanisms. Here, we report that treatment with Galectin-8 (Gal-8), a tandem-repeat member of the galectin family, reduces retinal pathology and prevents photoreceptor cell damage in a murine model of experimental autoimmune uveitis. Gal-8 treatment increased the number of regulatory T cells (Treg) in both the draining lymph node (dLN) and the inflamed retina. Moreover, a greater percentage of Treg cells in the dLN and retina of Gal-8 treated animals expressed the inhibitory coreceptor cytotoxic T lymphocyte antigen (CTLA)-4, the immunosuppressive cytokine IL-10, and the tissue-homing integrin CD103. Treg cells in the retina of Gal-8-treated mice were primarily inducible Treg cells that lack the expression of neuropilin-1. In addition, Gal-8 treatment blunted production of inflammatory cytokines by retinal T helper type (TH) 1 and TH17 cells. The effect of Gal-8 on T cell differentiation and/or function was specific for tissues undergoing an active immune response, as Gal-8 treatment had no effect on T cell populations in the spleen. Given the need for rational therapies for managing human uveitis, Gal-8 emerges as an attractive therapeutic candidate not only for treating retinal autoimmune diseases, but also for other TH1- and TH17-mediated inflammatory disorders | |
dc.language | eng | |
dc.publisher | Public Library Of Science | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0130772 | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1371/journal.pone.0130772 | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488339/ | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | GALECTIN 8 | |
dc.subject | REGULATORY CELL | |
dc.subject | OCULAR PATHOLOGY | |
dc.subject | IMMUNOSUPPRESSIVE AGENTS | |
dc.subject | CELL DIFFERENTIATION | |
dc.title | Galectin 8 ameliorates murine autoimmune ocular pathology and promotes a regulatory T cell response | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |